title: De novo generation of HSCs from somatic and pluripotent stem cell sources.
abstract: Generating human hematopoietic stem cells (HSCs) from autologous tissues, when coupled with genome editing technologies, is a promising approach for cellular transplantation therapy and for in vitro disease modeling, drug discovery, and toxicology studies. Human pluripotent stem cells (hPSCs) represent a potentially inexhaustible supply of autologous tissue; however, to date, directed differentiation from hPSCs has yielded hematopoietic cells that lack robust and sustained multilineage potential. Cellular reprogramming technologies represent an alternative platform for the de novo generation of HSCs via direct conversion from heterologous cell types. In this review, we discuss the latest advancements in HSC generation by directed differentiation from hPSCs or direct conversion from somatic cells, and highlight their applications in research and prospects for therapy.
authors.affiliation: Stem Cell Transplantation Program, Division of Hematology and Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
authors.forename: Linda T
authors.initials: LT
authors.lastname: Vo
authors.affiliation: Stem Cell Transplantation Program, Division of Hematology and Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
authors.forename: George Q
authors.initials: GQ
authors.lastname: Daley
mesh_terms: D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods; D002454:Cell Differentiation; D060846:Cell Engineering / Q000379:methods; D019070:Cell Lineage; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D065150:Cellular Reprogramming; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D039904:Pluripotent Stem Cells / Q000166:cytology* / Q000378:metabolism